Company profile
ONCOLYTICS BIOTECH INC
NASDAQ:ONCYBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PELAREOREP | phase3 | — | 15 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07280377 | phase1_2 | active_not_recruiting | 2021-10-27 | 2027-07-30 | Oncolytics Biotech | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
| NCT00998322 | phase2 | completed | 2009-10-01 | 2013-12-01 | Oncolytics Biotech | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma |
| NCT00998192 | phase2 | completed | 2009-10-01 | 2013-09-01 | Oncolytics Biotech | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung |
| NCT04215146 | phase2 | active_not_recruiting | 2020-06-10 | 2022-08-01 | Oncolytics Biotech | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study |
| NCT04102618 | — | terminated | 2019-03-29 | 2022-04-20 | Oncolytics Biotech | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer |
FDA applications (0)
No records yet.